Search results for " hormones"

showing 10 items of 405 documents

Mating-induced differential peptidomics of neuropeptides and protein hormones in Agrotis ipsilon moths

2018

International audience; In many insects, mating induces drastic changes in male and female responses to sex pheromones or host-plant odors. In the male moth Agrotis ipsilon, mating induces a transient inhibition of behavioral and neuronal responses to the female sex pheromone. As neuropeptides and peptide hormones regulate most behavioral processes, we hypothesize that they could be involved in this mating-dependent olfactory plasticity. Here we used next-generation RNA sequencing and a combination of liquid chromatography, matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and direct tissue profiling to analyze the transcriptome and peptidome of diffe…

Central Nervous SystemMaleProteomics0301 basic medicinePeptide HormonesCentral nervous systemNeuropeptideAgrotis ipsilonOlfactionsex pheromoneMothsPeptide hormoneBiochemistryTranscriptomeSexual Behavior Animal03 medical and health sciencesSex Factors0302 clinical medicinemedicineAnimalsAgrotis ipsilonmothtransciptomeChromatography High Pressure Liquidreproductive and urinary physiologypeptide predictionmass spectrometrybiology[SDV.BA]Life Sciences [q-bio]/Animal biologyneuropeptidesHigh-Throughput Nucleotide SequencingGeneral Chemistrybiology.organism_classificationCell biologymating030104 developmental biologymedicine.anatomical_structureSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationSex pheromoneplasticityPheromoneFemalePeptides030217 neurology & neurosurgeryolfaction
researchProduct

Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain inj…

2013

Following traumatic brain injury (TBI) neuroinflammatory processes promote neuronal cell loss. Alpha-melanocyte-stimulating hormone (α-MSH) is a neuropeptide with immunomodulatory properties, which may offer neuroprotection. Due to short half-life and pigmentary side-effects of α-MSH, the C-terminal tripeptide α-MSH(11-13) may be an anti-inflammatory alternative. The present study investigated the mRNA concentrations of the precursor hormone proopiomelanocortin (POMC) and of melanocortin receptors 1 and 4 (MC1R/MC4R) in naive mice and 15 min, 6, 12, 24, and 48 h after controlled cortical impact (CCI). Regulation of POMC and MC4R expression did not change after trauma, while MC1R levels incr…

Central Nervous SystemMaleendocrine systemAnatomy and PhysiologyPro-OpiomelanocortinMouseScienceAnti-Inflammatory AgentsGene ExpressionApoptosisNeurological SystemImmunomodulationMiceModel OrganismsNeurorehabilitation and TraumaAnimalsMelanocyte-Stimulating HormonesBiologyCalcium-Binding ProteinsMicrofilament ProteinsQRBrainAnimal ModelsPeptide FragmentsMice Inbred C57BLHead InjuryNeurologyImmune SystemBrain InjuriesNervous System ComponentsCytokinesReceptor Melanocortin Type 4MedicineClinical ImmunologyMicrogliaInflammation MediatorsReceptor Melanocortin Type 1hormones hormone substitutes and hormone antagonistsResearch ArticleNervous System PhysiologyPLoS ONE
researchProduct

Differential Promotion of Glutamate Transporter Expression and Function by Glucocorticoids in Astrocytes from Various Brain Regions

2005

Steroids that activate glucocorticoid receptors (GRs) and mineralocorticoid receptors have important regulatory effects on neural development, plasticity, and the body's stress response. Here, we investigated the role of corticosteroids in regulating the expression of the glial glutamate transporters glial glutamate transporter-1 (GLT-1) and glutamate-aspartate transporter (GLAST) in rat primary astrocytes. The synthetic glucocorticoid dexamethasone provoked a marked increase of GLT-1 transcription and protein levels in cortical astrocytes, whereas GLAST expression remained unaffected. Up-regulation of GLT-1 expression was accompanied by an enhanced glutamate uptake, which could be blocked …

Central Nervous SystemTime FactorsAmino Acid Transport System X-AGLigandsBiochemistryDexamethasoneRats Sprague-Dawleychemistry.chemical_compoundGlucocorticoid receptorMineralocorticoid receptorAdrenal Cortex HormonesCorticosteroneCerebellumGene expressionLuciferasesReceptorDNA Modification MethylasesKainic AcidReverse Transcriptase Polymerase Chain ReactionGlutamate receptorBrainImmunohistochemistryUp-RegulationMifepristoneAzacitidineNeurogliaGlucocorticoidmedicine.drugmedicine.medical_specialtymedicine.drug_classBlotting WesternDetergentsBiologyDecitabineTransfectionMembrane MicrodomainsInternal medicinemedicineAnimalsGlucocorticoidsMolecular BiologyDNA PrimersFluorescent DyesDose-Response Relationship DrugCell BiologyDNA MethylationRatsReceptors MineralocorticoidEndocrinologychemistryMineralocorticoidAstrocytesCorticosteroneJournal of Biological Chemistry
researchProduct

AISF position paper on liver disease and pregnancy.

2016

Abstract The relationship between liver disease and pregnancy is of great clinical impact. Severe liver disease in pregnancy is rare; however, pregnancy-related liver disease is the most frequent cause of liver dysfunction during pregnancy and represents a severe threat to foetal and maternal survival. A rapid differential diagnosis between liver disease related or unrelated to pregnancy is required in women who present with liver dysfunction during pregnancy. This report summarizes the recommendation of an expert panel established by the Italian Association for the Study of the Liver (AISF) on the management of liver disease during pregnancy. The article provides an overview of liver disea…

Cholagogues and CholereticsViral HepatitisBudd-Chiari SyndromeChronic liver diseaseAdrenal Cortex HormoneGastroenterologyHyperemesis gravidarumLiver disease0302 clinical medicinePre-EclampsiaAdrenal Cortex HormonesCholelithiasisMED/12 - GASTROENTEROLOGIAPregnancyHyperemesis GravidarumEclampsiaCholelithiasiThiaminePregnancy Complications InfectiousCholagogues and CholereticSocieties Medical030219 obstetrics & reproductive medicineFatty liverUrsodeoxycholic AcidGastroenterologyCalcium Channel BlockersLiver diseases; Pregnancy; Gastroenterology; HepatologyPregnancy ComplicationAntihypertensive AgentItalyVitamin B ComplexBudd–Chiari syndromeLiver diseases; Pregnancy030211 gastroenterology & hepatologyFemaleCalcium Channel BlockerLiver diseaseHumanViral Hepatitis Vaccinesmedicine.medical_specialtyHELLP SyndromeHepatitis Viral HumanHELLP syndromeCholestasis Intrahepatic03 medical and health sciencesMagnesium SulfateInternal medicinemedicineHumansIntensive care medicineAntihypertensive AgentsLiver diseasesPregnancyEclampsiaHepatologybusiness.industrymedicine.diseasePregnancy ComplicationsFatty LiverPregnancy Liver disease Viral HepatitisPregnancy Complications InfectiouFluid TherapybusinessViral Hepatitis Vaccine
researchProduct

Cabut/dTIEG associates with the transcription factor Yorkie for growth control

2015

The Drosophila transcription factor Cabut/dTIEG (Cbt) is a growth regulator, whose expression is modulated by different stimuli. Here, we determine Cbt association with chromatin and identify Yorkie (Yki), the transcriptional co-activator of the Hippo (Hpo) pathway as its partner. Cbt and Yki co-localize on common gene promoters, and the expression of target genes varies according to changes in Cbt levels. Down-regulation of Cbt suppresses the overgrowth phenotypes caused by mutations in expanded (ex) and yki overexpression, whereas its up-regulation promotes cell proliferation. Our results imply that Cbt is a novel partner of Yki that is required as a transcriptional co-activator in growth…

Chromatin ImmunoprecipitationdTIEGgrowthBiologyProtein Serine-Threonine KinasesReal-Time Polymerase Chain ReactionBiochemistrybehavioral disciplines and activitiesModels BiologicalCabutRegulació genèticamental disordersGeneticsAnimalsDrosophila ProteinsDrosòfila -- GenèticaNuclear proteinYorkieMolecular BiologyGeneTranscription factorGeneticsSequence Analysis RNAfungiScientific ReportsGAFIntracellular Signaling Peptides and ProteinsNuclear ProteinsPromoterYAP-Signaling ProteinsPhenotypeCell biologyChromatinbody regionsJuvenile HormonesTrans-ActivatorsDrosophilaSignal transductionChromatin immunoprecipitationSignal TransductionTranscription FactorsEMBO Reports
researchProduct

Quantification of ecdysteroids by immunoassay: comparison of enzyme immunoassay and radioimmunoassay.

1995

Abstract The performance of enzyme immunoassay (EIA) and radioimmunoassay (RIA) in the quantitative analysis of ecdysteroids was compared. The EIA was found to be at least equivalent to the RIA with respect to analytical range and sensitivity and to be more comfortable with respect to safety and time saving. When biological samples were analyzed by both assays a good correlation (r = 0.83) was found. Since the EIA has certain advantages over the RIA, we now recommend the use of the former assay for the quantification of ecdysteroids.

ChromatographyTime Factorsmedicine.diagnostic_testChemistryDipteraRadioimmunoassayEcdysteroidsRadioimmunoassayTime savingSensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologyImmunoenzyme TechniquesImmunoassayImmunoenzyme techniquesInsect HormonesLarvamedicineAnimalsSteroidsQuantitative analysis (chemistry)
researchProduct

Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of …

2022

Corticosteroids (CSs) are widely used in oncology, presenting several different indications. They are useful for induction of apoptosis in hematological neoplasms, for management of anaphylaxis and cytokine release/hypersensitivity reaction and for the symptomatic treatment of many tumour- and treatment-related complications. If the employment of CSs in the oncological setting results in several benefits for patients and satisfaction for clinicians, on the other hand, many potential adverse events (AEs), both during treatment and after withdrawal of CSs, as well as the duality of the effects of these compounds in oncology, recommend being cautious in clinical practice. To date, several gray…

ConsensusSurvivalTumour responseSettore MED/06 - Oncologia MedicaContraindicationsHematologyMedical OncologyItalyOncologyAdrenal Cortex HormonesDoseAdverse eventsHumansCorticosteroidsIndicationsGlucocorticoidsSocieties MedicalCancer
researchProduct

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

2013

Background Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), …

CyclopropanesLipopolysaccharidesMaleMAPK/ERK pathwaymedicine.medical_specialtyNeutrophilsPrimary Cell CultureImmunologyDrug ResistanceAminopyridinesGene ExpressionComplex MixturesDexamethasoneHistone DeacetylasesPhosphatidylinositol 3-KinasesPulmonary Disease Chronic ObstructiveGlucocorticoid receptorAdrenal Cortex HormonesInternal medicineTobaccomedicineHumansImmunology and AllergyMacrophage Migration-Inhibitory FactorsDexamethasoneActive metaboliteRoflumilastAgedCOPDbusiness.industryInterleukin-8Drug SynergismMiddle Agedmedicine.diseaseIntramolecular OxidoreductasesEndocrinologyMatrix Metalloproteinase 9BenzamidesMitogen-Activated Protein Kinase PhosphatasesFemaleMacrophage migration inhibitory factorPhosphodiesterase 4 InhibitorsbusinessBiomarkersGlucocorticoidmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct